Combined Theta-gamma STN Stimulation for Verbal Fluency in Parkinson Disease
NCT ID: NCT06509048
Last Updated: 2024-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2023-11-10
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Preliminary evidence from pilot studies suggested that low frequency theta oscillations (4-10 Hz) within the STN and correlated cortical networks are important in cognition, including verbal fluency, color-word interference, and spatial and episodic memory; cortical structures involved in category verbal fluency encompass not only the prefrontal cortex, but also the hippocampus and related medial temporal structures. There is also evidence that theta STN stimulations lead to a worsening of motor symptoms, compared with no stimulation and therapeutic stimulation (gamma frequency).
To date, new DBS systems allow the use of multiple current sources and/or frequency settings at different depths and directions in a single electrode, and then to combine different stimulation frequencies.
Considering this, the aim is to evaluate the use of combined high (gamma) and very low (theta) frequency stimulation in a randomized, cross-over, double-blind trial with this principal research questions:
1. Can combined theta-gamma theta frequency STN stimulation improve verbal fluency in PD patients?
2. Can combined theta-gamma frequency STN stimulation improve verbal frequency without worsening cardinal motor symptoms?
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be randomly assigned to one of two sequences: Group 1 will receive standard DBS first followed by theta-gamma DBS, while Group 2 will receive theta-gamma DBS first followed by standard DBS. This design ensures that each patient serves as their own control, thereby reducing variability and enhancing the accuracy of the findings. A computer program will generate the randomization list.
One investigator, in charge of changing DBS parameter settings, will be unblinded to stimulation parameters and aware of the randomization sequence. The theta-gamma stimulation will be set maintaining the classical stimulation of the patient (gamma frequency, 100-180 Hz), with bilateral addiction of a ventral contact for stimulation with theta frequency (4-10 Hz).
Two investigators, blinded to stimulation parameters and randomization sequence, will conduct clinical and neuropsychological assessments.
The unblinded investigator will decide on a possible switch to the next sequence if the symptoms will not be well tolerated by the patient. In case of persistent worsening even after the second modification, the patient will be dropped out from the study. Dopaminergic therapy will be stable during the study course.
The clinical and neuropsychological test battery will include: motor state, evaluated with the Movement Disorder Society - Unified Parkinson Disease Rating Scale (MDS-UPDRS); Cognitive screening test, as per Mini Mental State Examination (MMSE); Beck Depression Inventory - Short Form (BDI-SF); Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS); Phonemic and semantic verbal fluency test (letter, episodic category, non-episodic category, and category switching).
The neuropsychological test battery will be conducted at baseline and at the end of first and second month of evaluation. The verbal fluency evaluation will be conducted also one hour after the change of stimulation parameters, to also evaluate its impact at a short time distance.
The evaluation will be conducted in the morning, during the ON phase, in order to avoid possible effects of wearing-off on cognitive performance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Stimulation
Standard STN-DBS stimulation
No interventions assigned to this group
Theta-Gamma Stimulation
Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
STN-DBS Theta Gamma Stimulation
Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STN-DBS Theta Gamma Stimulation
Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Optimized DBS therapy in the last month,
* Stable medication regimen in the last month
* Able to provide informed consent
* Fluent in Italian
* Able to complete cognitive testing
* Patients implanted with bilateral Vercise Cartesia™ Directional Leads in the STN connected to a Vercise™ or Vercise Gevia™ or Vercise Genus™ DBS system
Exclusion Criteria
* Major substance abuse,
* Stimulation provided in the more ventral contact
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Turin, Italy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maurizio Zibetti
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maurizio Zibetti
Role: PRINCIPAL_INVESTIGATOR
AOU Città della Salute e della scienza Torino
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AOU Città della Salute e della Scienza Torino
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Theta-Gamma DBS
Identifier Type: -
Identifier Source: org_study_id